We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

AbbVie Gets Humira Patent Invalidated As Obvious

Law360, New York (June 26, 2013, 6:32 PM EDT) -- AbbVie Inc. has won a ruling in New York federal court declaring invalid a patent for the anti-inflammatory drug Humira held by the Mathilda and Terence Kennedy Institute of Rheumatology Trust, meaning the drugmaker no longer will have to pay the trust licensing fees.

U.S. District Judge Paul A. Crotty ruled June 20 that the trust's U.S. Patent Number 7,846,442, which covers the cocktail of ingredients that make up Humira, was invalid for obviousness-type double patenting. Judge Crotty presided over the four-day bench trial last fall.

AbbVie, which produces and markets Humira, used to do so under a licensing agreement with...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Attached Documents


Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.



Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


New York Southern

Nature of Suit



Subscribers Only

Date Filed

April 13, 2011

Law Firms


Government Agencies